3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1
4
Phase 3
2
Phase 1/2
2
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Cisplatin
14
Carboplatin
12
Magnetic Resonance Spectroscopy
11
Specimen Handling
10
Gemcitabine
10
pembrolizumab
8
Pemetrexed
8
atezolizumab
7
Paclitaxel
7
Radiotherapy, Intensity-Modulated
5
Platinum
5
Nivolumab
5
Immunoglobulin G
5
Doxorubicin
5
Docetaxel
5
Disulfides
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
1,2-diaminocyclohexaneplatinum II citrate
5
Cetuximab
4
Biopsy
4
durvalumab
3
Temozolomide
3
Standard of Care
3
Rituximab
3
Drug Therapy
3
Dexamethasone
3
Cyclophosphamide
3
(225)Ac-DOTA-c(RGDyK)
3
venetoclax
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Granulocyte Colony-Stimulating Factor
×
30 days
×
Clear all
NCT05139017
2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
290 enrolled